by The global Swine Vaccines market size is expected to be worth around US$ 6.5 billion by 2030, according to a new report by Vision Research Reports.
The global Swine Vaccines market size was valued at US$ 2.45 billion in 2020 and is anticipated to grow at a CAGR of 5.9% during forecast period 2021 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39081
Table of Contents
Swine Vaccines Market Growth Factors
Increasing prevalence of diseases, a surge in the demand for animal protein, and growth in R&D expenditure for vaccines innovation are driving the market growth. Porcine Parvovirus (PPV), Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine circovirus type 2 (PCV2), Foot & Mouth Disease, Classical Swine Fever, and others remain to be extremely prevalent diseases in pig farms affecting economic losses.
Swine production is a key component of global food security, agricultural countries, and local & international business. Contagious diseases impact pig health and stability and productivity of the swine industry globally. Thus, the rising prevalence of diseases in swine is estimated to drive the market over the forecast years. Porcine Parvovirus (PPV) is a reproductive disease present in most pig farms globally. Porcine Reproductive and Respiratory Syndrome (PRRS) remains to be a highly prevalent disease in pig farms affecting economic losses through its adverse effects on reproduction and growth as well as by clinical illness.
Swine Vaccines Market Report Coverage
| Report Scope | Details |
| Market Size | US$ 6.5 billion by 2030 |
| Growth Rate | CAGR of 5.9% From 2021 to 2030 |
| Largest Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Product, Type |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Merck Animal Health; Ceva; Zoetis; BoehringerIngelheim GmbH; Elanco; Indian Immunologicals Ltd.; BiogénesisBagó; Phibro Animal Health; KM Biologics; HIPRA |
By Product Analysis
The inactivated vaccines segment dominated the global market in 2020 with a revenue share of more than 38% in 2020. This is attributed to the easy availability, low cost, minimal risk of revert reaction of killed viruses, and new improvements by key players.
The recombinant vaccine segment is expected to exhibit the fastest CAGR from 2021 to 2028. These vaccines are anticipated to assist in achieving vaccination against several virus strains, as recombinants can carry numerous gene inserts.
By Type Analysis
The Porcine Circovirus type 2 (PCV2) dominated the global market with a revenue share of more than 14% in 2020. Transmission of PCV-2 may be by direct contact with an infected pig. PCV2 is the quickly mutating of all single-stranded DNA (ssDNA) viruses and thus, has a great mutation and recombination rate.
The foot & mouth disease segment is expected to witness the second-fastest CAGR over the forecast period. In swine, foot-and-mouth disease is an epidemic that has a substantial effect on food safety and animal husbandry.
By Regional Analysis
Asia Pacific accounted for the maximum revenue share of more than 46% in 2020 and is anticipated to register the fastest CAGR during the forecast period. Middle-income nations, especially Southeast Asian countries, consume greater amounts of meat and the meat consumption of pork is still on the rise.
North America held a significant revenue share in 2020. The presence of well-established veterinary healthcare infrastructure, increased demand for animal protein, highly organized farming structure, and rising expenditure on animal health is attributed to the region’s growth.
Read also @ Companion Animal Medicine Market Insight and Trends 2030
Major Key Players Covered in The Swine Vaccines Market Report include
- Merck Animal Health
- Ceva
- Zoetis
- Boehringer Ingelheim GmbH
- Elanco
- Indian Immunologicals Ltd.
- BiogénesisBagó
- Phibro Animal Health
- KM Biologics
- HIPRA
Swine Vaccines Market Segmentation
- By Type
- Swine Influenza
- Classical Swine Fever
- Porcine Parvovirus
- Porcine Circovirus Type 2
- M.Hyo
- ActinobacillusPleuropneumonia
- PRRS
- Foot & Mouth Disease
- Pseudorabies
- PEDV
- Others
- By Product
- Attenuated Live Vaccines
- Inactivated Vaccines
- Subunit Vaccines
- DNA Vaccines
- Recombinant Vaccines
- Regional
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Asia Pacific
- Japan
- China
- India
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East and Africa (MEA)
- Saudi Arabia
- South Africa
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Swine Vaccines Market, By Type
7.1. Swine Vaccines Market, by Type, 2021-2030
7.1.1. Swine Influenza
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Classical Swine Fever
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Porcine Parvovirus
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Porcine Circovirus Type 2
7.1.4.1. Market Revenue and Forecast (2017-2030)
7.1.5. M.Hyo
7.1.5.1. Market Revenue and Forecast (2017-2030)
7.1.6. ActinobacillusPleuropneumonia
7.1.6.1. Market Revenue and Forecast (2017-2030)
7.1.7. PRRS
7.1.7.1. Market Revenue and Forecast (2017-2030)
7.1.8. Foot & Mouth Disease
7.1.8.1. Market Revenue and Forecast (2017-2030)
7.1.9. Pseudorabies
7.1.9.1. Market Revenue and Forecast (2017-2030)
7.1.10. PEDV
7.1.10.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Swine Vaccines Market, By Product
8.1. Swine Vaccines Market, by Product, 2021-2030
8.1.1. Attenuated Live Vaccines
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Inactivated Vaccines
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Subunit Vaccines
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. DNA Vaccines
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Recombinant Vaccines
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Swine Vaccines Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Type (2017-2030)
9.1.2. Market Revenue and Forecast, by Product (2017-2030)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, by Type (2017-2030)
9.1.3.2. Market Revenue and Forecast, by Product (2017-2030)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, by Type (2017-2030)
9.1.4.2. Market Revenue and Forecast, by Product (2017-2030)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Type (2017-2030)
9.2.2. Market Revenue and Forecast, by Product (2017-2030)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, by Type (2017-2030)
9.2.3.2. Market Revenue and Forecast, by Product (2017-2030)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, by Type (2017-2030)
9.2.4.2. Market Revenue and Forecast, by Product (2017-2030)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, by Type (2017-2030)
9.2.5.2. Market Revenue and Forecast, by Product (2017-2030)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, by Type (2017-2030)
9.2.6.2. Market Revenue and Forecast, by Product (2017-2030)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Type (2017-2030)
9.3.2. Market Revenue and Forecast, by Product (2017-2030)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, by Type (2017-2030)
9.3.3.2. Market Revenue and Forecast, by Product (2017-2030)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, by Type (2017-2030)
9.3.4.2. Market Revenue and Forecast, by Product (2017-2030)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, by Type (2017-2030)
9.3.5.2. Market Revenue and Forecast, by Product (2017-2030)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, by Type (2017-2030)
9.3.6.2. Market Revenue and Forecast, by Product (2017-2030)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Type (2017-2030)
9.4.2. Market Revenue and Forecast, by Product (2017-2030)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, by Type (2017-2030)
9.4.3.2. Market Revenue and Forecast, by Product (2017-2030)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, by Type (2017-2030)
9.4.4.2. Market Revenue and Forecast, by Product (2017-2030)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, by Type (2017-2030)
9.4.5.2. Market Revenue and Forecast, by Product (2017-2030)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, by Type (2017-2030)
9.4.6.2. Market Revenue and Forecast, by Product (2017-2030)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Type (2017-2030)
9.5.2. Market Revenue and Forecast, by Product (2017-2030)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, by Type (2017-2030)
9.5.3.2. Market Revenue and Forecast, by Product (2017-2030)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, by Type (2017-2030)
9.5.4.2. Market Revenue and Forecast, by Product (2017-2030)
Chapter 10. Company Profiles
10.1. Merck Animal Health
10.1.1. Company Overview
10.1.2. Type Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Ceva
10.2.1. Company Overview
10.2.2. Type Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Zoetis
10.3.1. Company Overview
10.3.2. Type Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Boehringer Ingelheim GmbH
10.4.1. Company Overview
10.4.2. Type Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Elanco
10.5.1. Company Overview
10.5.2. Type Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Indian Immunologicals Ltd.
10.6.1. Company Overview
10.6.2. Type Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. BiogénesisBagó
10.7.1. Company Overview
10.7.2. Type Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Phibro Animal Health
10.8.1. Company Overview
10.8.2. Type Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. KM Biologics
10.9.1. Company Overview
10.9.2. Type Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. HIPRA
10.10.1. Company Overview
10.10.2. Type Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
12.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39081
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
